Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-17T13:20:52.965Z Has data issue: false hasContentIssue false

Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series

Published online by Cambridge University Press:  16 April 2020

K.N. Roy Chengappa*
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA Special Studies Center at Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017, USA Stanley Center for the Innovative Treatment of Bipolar Disorder, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
J. Levine
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA Special Studies Center at Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017, USA Stanley Center for the Innovative Treatment of Bipolar Disorder, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
D. Rathore
Affiliation:
Special Studies Center at Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017, USA
H. Parepally
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA Special Studies Center at Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017, USA
R. Atzert
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA Special Studies Center at Mayview State Hospital, 1601 Mayview Road, Bridgeville, PA 15017, USA
*
*Correspondence and reprints. E-mail address: [email protected] (K.N. Roy Chengappa).
Get access

Summary

Topiramate is an antiepileptic agent, which is being investigated as a mood-stabilizer. Three obese individuals with DSM-IV bipolar I disorder and type II diabetes mellitus received topiramate treatment in combination with antipsychotics and valproate or carbamazepine. In addition to improved mood stability, these individuals lost between 16 to 20.5% of their pre-topiramate body weight and also achieved significant glycemic control.

Type
Original article
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cassidy, F., Ahearn, E., Carroll, B.J.Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psych 1999; 156: 1417-1420.Google ScholarPubMed
Chengappa, K.N.R., Rathore, D., Levine, J., Atzert, R., Solai, L., Parepally, H.et alTopiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53.CrossRefGoogle ScholarPubMed
Hamilton, M.Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.CrossRefGoogle ScholarPubMed
Kusumakar, V., Yatham, L., Kutcher, S., O'Donovan, C.Preliminary, open-label study of topiramate in rapid cycling bipolar women. Eur Neropsychopharmacol 1999; 9: S357-S357.CrossRefGoogle Scholar
McElroy, S.L., Suppes, T., Keck, P.E., Frye, M.A., Denicoff, K.D., Altshuler, L.L.et alOpen-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-1033.CrossRefGoogle ScholarPubMed
Marcotte, D.Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245-251.CrossRefGoogle ScholarPubMed
Mukherjee, S., Rosen, A.M., Caracci, G., Shukla, S.Persistent tardive dyskinesia in bipolar patients. Arch Gen Psych 1986; 43: 342-346.CrossRefGoogle ScholarPubMed
Mukherjee, S., Schnur, D.B., Reddy, R.Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 1: 495-495.CrossRefGoogle ScholarPubMed
Spearing, M.K., Post, P.M., Leverich, G.S., Brandt, D., Nolen, W.Modification of the Clinical Clobal Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatric Res 1997; 73: 159-171.CrossRefGoogle Scholar
Woerner, M.G., Saltz, B.L., Kane, J.M., Lieberman, J.A., Alvir, J.M.Diabetes and development of tardive dyskinesia. Am J Psych 1993; 150: 966-968.Google ScholarPubMed
Young, R.C., Biggs, J.T., Zeigler, V.E., Meyer, D.A.A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.